Minor pathological changes are induced by naltrexone-poly(DL-lactide) implants in pregnant rats

Journal of Biomedical Materials Research - Part A

Volumn 91, Issue 4, 2009, Pages 964-974

  Farid, W O ^a   McCallum, D ^b   Tait, R J ^a   Dunlop, S A ^a,c   Hulse, G K ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Biocompatibility; Naltrexone poly(DL lactide) implant; Pregnancy; Rats; Sustained release

Indexed keywords

CHRONIC INFLAMMATORY; DL-LACTIDE; DOSE-DEPENDENT MANNER; FOREIGN BODY REACTIONS; HISTOLOGICAL CHANGES; LIMITED DATA; LOW LEVEL; NALTREXONE; PATHOLOGICAL CHANGES; PATIENT COMPLIANCE; PREGNANCY; PREGNANT RAT; SLOW RELEASE; SUSTAINED-RELEASE; TISSUE ASSESSMENTS; TISSUE RESPONSE; WESTERN AUSTRALIA;

BIOCOMPATIBILITY; OBSTETRICS; POLYMERS;

RATS;

NALTREXONE; POLY[TRANS 3,6 DIMETHYL 1,4 DIOXYANE 2,5 DIONE]; POLYMER; UNCLASSIFIED DRUG;

ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; FIBROSIS; FOREIGN BODY REACTION; HEROIN DEPENDENCE; HISTOLOGY; IMPLANTATION; NONHUMAN; PATHOLOGY; PREGNANCY; RAT; SUSTAINED DRUG RELEASE;

ANIMALS; BIOCOMPATIBLE MATERIALS; BIREFRINGENCE; FEMALE; FOREIGN-BODY REACTION; IMPLANTS, EXPERIMENTAL; INFLAMMATION; MALE; NALTREXONE; POLYESTERS; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; SKIN;

EID: 70450192931     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32283     Document Type: Article

References (69)

1. Martin W, Bell J, Gilbert P, Sloan J, Thompson J. The effects of naltrexone in the chronic spinal dog and acute spinal cat; possible interaction with naturally-occurring morphine-like agonists. NIDA Res Monogr 1976;9:27-30.
2. Wentland MP, Lou R, Dehnhardt CM, Duan W, Cohen DJ, Bidlack JM. 3-Carboxamido analogues of morphine and naltrexone. Synthesis and opioid receptor binding properties. Bioorg Med Chem Lett 2001;11:1717-1721.
3. Tucker T, Ritter A, Maher C, Jackson H. Naltrexone maintenance for heroin dependence: Uptake, attrition and retention. Drug Alcohol Rev 2004;23:299-309. (Pubitemid 39305499)
4. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 2002;38:351-376. (Pubitemid 34219111)
5. Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: A report of two cases. Addict Biol 2002;7:321-323. (Pubitemid 34848420)
6. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 2002;159:351-360.
7. Galloway GP, Koch M, Cello R, Smith DE. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: An open-label trial. BMC Psychiatry 2005;5:18. (Pubitemid 41460708)
8. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004;28:1051-1059. (Pubitemid 38955203)
9. Bell JR, Young MR, Masterman SC, Morris A, Mattick RP, Bammer G. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust 1999;171:26-30. (Pubitemid 29342244)
10. San L, Pomarol G, Peri JM, Olle JM, Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991;86:983-990.
11. Johnson BA, Ait-Daoud N, Aubin HJ, Van Den Brink W, Guzzetta R, Loewy J, Silverman B, Ehrich E. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004;28:1356-1361. (Pubitemid 39238294)
12. Bartus RT, Emerich DF, Hotz J, Blaustein M, Dean RL, Perdomo B, Basile AS. Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology 2003;28:1973-1982. (Pubitemid 37412106)
13. Yolles S, Leafe TD, Woodland JH, Meyer FJ. Long acting delivery systems for narcotic antagonists II: Release rates of naltrexone from poly(lactic acid) composites. J Pharm Sci 1975;64:348-349.
14. Sharon AC, Wise DL. Development of drug delivery systems for use in treatment of narcotic addiction. NIDA Res Monogr 1981;28:194-213. (Pubitemid 12235221)
15. Chiang CN, Hollister LE, Kishimoto A, Barnett G. Kinetics of a naltrexone sustained-release preparation. Clin Pharmacol Ther 1984;36:704-708.
16. Maa YF, Heller J. Controlled release of naltrexone pamoate from linear poly(ortho esters). J Control Release 1990;14:21-28. (Pubitemid 20305837)
17. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA 2005;293:1617-1625. (Pubitemid 40471792)
18. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson RC. Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants. Addict Biol 2004;9:67-72. (Pubitemid 38608488)
19. Hulse GK, Arnold-Reed DE, O'Neil G, Hansson RC. Naltrexone implant and blood naltrexone levels over pregnancy. Aust N Z J Obstet Gynaecol 2003;43:386-388. (Pubitemid 37304235)
20. Anderson JM, Langone JJ. Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems. J Control Release 1999;57:107-113.
21. Yamaguchi K, Anderson JM. Biocompatibility studies of naltrexone sustained release formulations. J Control Release 1992;19:299-314.
22. Alim TN, Tai B, Chiang CN, Green T, Rosse RB, Lindquist T, Deutsch SI. Tolerability Study of a Depot Form of Naltrexone Substance Abusers. Toronto, Canada: National Institutes of Health; 1995.
23. Nuwayser ES, DeRoo DJ, Balskovich PD, Tsuk AG. Sustained release injectable naltrexone microcapsules. NIDA Res Monogr 1990;105:532-533.
24. Hulse GK, Stalenberg V, McCallum D, Smit W, O'Neil G, Morris N, Tait RJ. Histological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humans. J Control Release 2005;108:43-55. (Pubitemid 41476673)
25. Caswell A. MIMS Bi-Monthly. Sydney, Australia: CMP-Medica Australia; 2005.
26. Hulse G, O'Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol 2002;42:569-573. (Pubitemid 35385713)
27. Gretzer C, Emanuelsson L, Liljensten E, Thomsen P. The inflammatory cell influx and cytokines changes during transition from acute inflammation to fibrous repair around implanted materials. J Biomater Sci Polym Ed 2006;17:669-687. (Pubitemid 44069701)
28. Gomar C, Fernandez C. Epidural analgesia-anaesthesia in obstetrics. Eur J Anaesthesiol 2000;17:542-558.
29. Hoehner PJ. Ethical aspects of informed consent in obstetric anesthesia-new challenges and solutions. J Clin Anesth 2003;15:587-600. (Pubitemid 38064279)
30. Gein SV, Sharav'eva IL, Tendryakova SP. Role of delta-opioid receptors in the regulation of humoral and cell-mediated immune response in rotational stress. Dokl Biol Sci 2006;407:119-120.
31. Shavit Y, Depaulis A, Martin FC, Terman GW, Pechnick RN, Zane CJ, Gale RP, Liebeskind JC. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc Natl Acad Sci USA 1986;83:7114-7117. (Pubitemid 17172840)
32. Doria A, Iaccarino L, Arienti S, Ghirardello A, Zampieri S, Rampudda ME, Cutolo M, Tincani A, Todesco S. Th2 immune deviation induced by pregnancy: The two faces of autoimmune rheumatic diseases. Reprod Toxicol 2006;22:234-241. (Pubitemid 43994383)
33. Entrican G. Immune regulation during pregnancy and hostpathogen interactions in infectious abortion. J Comp Pathol 2002;126:79-94. (Pubitemid 35049263)
34. Arck PC. Stress and pregnancy loss: Role of immune mediators, hormones and neurotransmitters. Am J Reprod Immunol 2001;46:117-123.
35. Zuckerman L, Rehavi M, Nachman R, Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: A novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 2003;28:1778-1789. (Pubitemid 41070843)
36. Frank P, Schoenhard GL, Burton E. A method for rapid and frequent blood collection from the rat tail vein. J Pharmacol Methods 1991;26:233-238.
37. Belanger MC, Marois Y. Hemocompatibility, biocompatibility, inflammatory and in vivo studies of primary reference materials low-density polyethylene and polydimethylsiloxane: A review. J Biomed Mater Res 2001;58:467-477. (Pubitemid 32899901)
38. Voskerician G, Gingras PH, Anderson JM. Macroporous condensed poly(tetrafluoroethylene). I. In vivo inflammatory response and healing characteristics. J Biomed Mater Res A 2006;76:234-242.
39. Darlington RB, Dunlop SA, Finlay BL. Neural development in metatherian and eutherian mammals: Variation and constraint. J Comp Neurol 1999;411:359-368.
40. Liu Y, Sunderland VB, O'Neil AG. In vitro and in vivo release of naltrexone from biodegradable depot systems. Drug Dev Ind Pharm 2006;32:85-94.
41. Robinson SR, Dreher B. The visual pathways of eutherian mammals and marsupials develop according to a common timetable. Brain Behav Evol 1990;36:177-195. (Pubitemid 20377674)
42. Finlay BL, Darlington RB. Linked regularities in the development and evolution of mammalian brains. Science 1995;268:1578-1584.
43. Ngo HT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry 2008;32;23-28.
44. Siepmann J, Faisant N, Akiki J, Richard J, Benoit JP. Effect of the size of biodegradable microparticles on drug release: Experiment and theory. J Control Release 2004;96:123-134. (Pubitemid 38438495)
45. Stayton PS, El-Sayed ME, Murthy N, Bulmus V, Lackey C, Cheung C, Hoffman AS. 'Smart' delivery systems for biomolecular therapeutics. Orthod Craniofac Res 2005;8:219-225.
46. Bertolotti M, Ferrari A, Vitale G, Stefani M, Trenti T, Loria P, Carubbi F, Carulli N, Sternieri E. Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J Hepatol 1997;27:505-511. (Pubitemid 27390898)
47. Verebey K, Mule SJ. Naltrexone pharmacology, pharmacokinetics, and metabolism: Current status. Am J Drug Alcohol Abuse 1975;2:357-363.
48. Wall ME, Perez-Reyes M, Brine DR, Cook CE. Naltrexone disposition in man after subcutaneous administration. Drug Metab Dispos 1984;12:677-682. (Pubitemid 15222670)
49. Misra AL, Bloch R, Vardy J, Mule SJ, Verebely K. Disposition of (15,16-3H)naltrexone in the central nervous system of the rat. Drug Metab Dispos 1976;4:276-280.
50. Yoburn BC, Cohen AH, Inturrisi CE. Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. J Pharmacol Exp Ther 1986;237:126-130.
51. Yamaguchi K, Anderson JM. In vivo biocompatibility studies of medisorb 65/35 D,L-lactide/glycolide copolymer microspheres. J Control Release 1993;24:81-93.
52. Piskin E. Biodegradable polymers as biomaterials. J Biomater Sci Polym Ed 1995;6:775-795.
53. Simon JA, Ricci JL, Di Cesare PE. Bioresorbable fracture fixation in orthopedics: A comprehensive review. Part I. Basic science and preclinical studies. Am J Orthop 1997;26:665-671.
54. Chuang LF, Chuang TK, Killam KF Jr, Chuang AJ, Kung HF, Yu L, Chuang RY. Delta opioid receptor gene expression in lymphocytes. Biochem Biophys Res Commun 1994;202:1291-1299. (Pubitemid 124009286)
55. Chuang LF, Chuang TK, Killam KF Jr, Qiu Q, Wang XR, Lin JJ, Kung HF, Sheng W, Chao C, Yu L, Chuang RY. Expression of kappa opioid receptors in human and monkey lymphocytes. Biochem Biophys Res Commun 1995;209:1003-1010.
56. Sedqi M, Roy S, Ramakrishnan S, Elde R, Loh HH. Complementary DNA cloning of a mu-opioid receptor from rat peritoneal macrophages. Biochem Biophys Res Commun 1995;209:563-574.
57. Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH, Roy S. The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the mu-opioid receptor. J Leukoc Biol 2002;71:782-790.
58. Budd K, Shipton EA. Acute pain the immune system and opioimmunosuppression. Acute Pain 2004;6:123-135.
59. Szabo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, Rogers TJ. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp Ther 1993;267:703-706. (Pubitemid 23352527)
60. Taub DD, Eisenstein TK, Geller EB, Adler MW, Rogers TJ. Immunomodulatory activity of mu- and kappa-selective opioid agonists. Proc Natl Acad Sci USA 1991;88:360-364.
61. Jankovic BD, Radulovic J. Quaternary naltrexone: Its immunomodulatory activity and interaction with brain delta and kappa opioid receptors. Immunopharmacology 1994;28:105-112. (Pubitemid 24277387)
62. Radulovic J, Mancev Z, Stanojevic S, Vasiljevic T, Kovacevic-Jovanovic V, Pesic G. Modulation of humoral immune response by central administration of leucine-enkephalin: Effects of mu, delta and kappa opioid receptor antagonists. J Neuroimmunol 1996;65:155-161. (Pubitemid 126334865)
63. van Kampen CA, Versteeg-vd Voort Maarschalk MF, Langerak-Langerak J, Roelen DL, Claas FH. Kinetics of the pregnancy-induced humoral and cellular immune response against the paternal HLA class I antigens of the child. Hum Immunol 2002;63:452-458. (Pubitemid 34620080)
64. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA 1995;273:1933-1936.
65. Hennen G, Frankenne F, Closset J, Gomez F, Pirens G, el Khayat N. A human placental GH: Increasing levels during second half of pregnancy with pituitary GH suppression as revealed by monoclonal antibody radioimmunoassays. Int J Fertil 1985;30:27-33. (Pubitemid 15238227)
66. Piccinni MP. Role of immune cells in pregnancy. Autoimmunity 2003;36:1-4.
67. Moreau P, Paul P, Rouas-Freiss N, Kirszenbaum M, Dausset J, Carosella ED. Molecular and immunologic aspects of the nonclassical HLA class I antigen HLA-G: Evidence for an important role in the maternal tolerance of the fetal allograft. Am J Reprod Immunol 1998;40:136-144.
68. Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997;18:478-482. (Pubitemid 27441590)
69. Luppi P. How immune mechanisms are affected by pregnancy. Vaccine 2003;21:3352-3357. (Pubitemid 36792085)